About: Odanacatib     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz:8890 associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Odanacatib
rdfs:subClassOf
Concept_In_Subset
Semantic_Type
  • Pharmacologic Substance
Preferred_Name
  • Odanacatib
UMLS_CUI
  • C2351970
CAS_Registry
  • 603139-19-1
In_Clinical_Trial_For
  • Bone metastases
FDA_UNII_Code
  • N673F6W2VH
Contributing_Source
  • FDA
PDQ_Open_Trial_Search_ID
  • 531150
PDQ_Closed_Trial_Search_ID
  • 531150
Chemical_Formula
  • C25H27F4N3O3S
Legacy_Concept_Name
  • MK0822
FULL_SYN
  • MK0822CNNCI
  • ODANACATIBPTFDAN673F6W2VH
  • (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamideSNNCI
  • OdanacatibPTNCI
DEFINITION
  • An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption.NCI
code
  • C66981
http://linked.open...y/mesh/hasConcept
Faceted Search & Find service v1.16.121 as of Mar 31 2025


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3240 as of Mar 31 2025, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 13 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software